Clinical Trials
17 trialsNCT02592317 2026-05-08
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT06788509 2026-05-08
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT04597411 2026-04-30
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Phase 1 Active not recruiting
NCT05997615 2026-04-20
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT06242470 2026-02-05
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Recruiting
NCT06067841 2026-02-04
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 1 Recruiting
NCT05519449 2026-01-20
ENGAGER-PSMA-01
Janux Therapeutics
Phase 1 Recruiting
NCT04428788 2025-12-22
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Celgene
Phase 1 Completed
NCT05252390 2025-11-06
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT05293496 2025-10-14
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Completed
NCT02204072 2025-07-15
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
Phase 1 Completed
NCT04249947 2025-02-17
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
Phase 1 Terminated
NCT02625857 2025-02-03
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT04404140 2023-10-17
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hoffmann-La Roche
Phase 1 Terminated
NCT04541225 2023-07-14
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT03551782 2022-02-25
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT02162836 2020-04-27
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Pharmaceutical K.K.
Phase 1 Completed